DRW Securities LLC Acquires New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

DRW Securities LLC bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,987 shares of the biotechnology company’s stock, valued at approximately $74,000.

A number of other hedge funds also recently added to or reduced their stakes in BCRX. Victory Capital Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 31.5% during the fourth quarter. Victory Capital Management Inc. now owns 26,842 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 6,434 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in BioCryst Pharmaceuticals by 9.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,594,436 shares of the biotechnology company’s stock worth $9,551,000 after purchasing an additional 133,629 shares during the period. Norges Bank purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth about $13,278,000. Capstone Investment Advisors LLC acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $112,000. Finally, Rafferty Asset Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 18.3% in the 4th quarter. Rafferty Asset Management LLC now owns 955,587 shares of the biotechnology company’s stock valued at $5,724,000 after buying an additional 147,699 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Finally, StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.63 on Wednesday. The company has a fifty day moving average of $7.81 and a two-hundred day moving average of $6.40. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The company has a market capitalization of $1.57 billion, a PE ratio of -7.13 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The firm had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same period last year, the company earned ($0.24) earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.45 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.